Health, pharma, science writer for Reuters. Any opinions are mine.

AstraZeneca a bid target again? CEO says someone may spot value

uk.reuters.com — LONDON AstraZeneca (AZN.L) declined to comment on Thursday on whether the drugmaker could become a takeover target once more, two years after it saw off a bid from Pfizer (PFE.N). This time speculation has moved to the idea of a possible offer from Swiss-based Novartis (NOVN.S), which would increase its cancer drug operations significantly by acquiring its smaller British rival.

UPDATE 1-AstraZeneca a bid target again? CEO says someone may spot value

reuters.com — (Adds further comments from AstraZeneca and Novartis CEOs) By Ben Hirschler LONDON, July 28 AstraZeneca's chief executive believes a rival could spot the growing value of its drug pipeline but declined to say if the group was likely to be a takeover target once more, two years after seeing off a bid from Pfizer.

AstraZeneca helped by new drugs as cholesterol pill fades

wkzo.com — By Ben Hirschler LONDON (Reuters) - Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter core earnings down by nearly a third at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes. The profit drop had been expected, however, and investors took heart from encouraging ea...

AstraZeneca helped by new drugs as cholesterol pill fades

dailymail.co.uk — LONDON, July 28 (Reuters) - Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter core earnings down by nearly a third at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes.

AstraZeneca helped by new drugs as cholesterol pill fades

uk.news.yahoo.com — By Ben Hirschler LONDON (Reuters) - Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter core earnings down by nearly a third at drugmaker AstraZeneca , which is now banking on new cancer medicines to revive its fortunes. Its new lung cancer drug Tagrisso achieved

AstraZeneca helped by new drugs as cholesterol pill fades

wixx.com — By Ben Hirschler LONDON (Reuters) - Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter core earnings down by nearly a third at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes. The profit drop had been expected, however, and investors took heart from encouraging ea...

AstraZeneca helped by new drugs as cholesterol pill fades

reuters.com — LONDON Generic competition to cholesterol fighter Crestor in the key U.S. market hit second-quarter earnings at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes. Core earnings per share, which exclude some items, fell 31 percent to 83 cents as revenue slid 11 percent $5.60 billion, following the arrival of the first copies of Crestor in the United States in May.

AstraZeneca helped by new drugs as cholesterol pill fades

metro.us — By Ben Hirschler LONDON (Reuters) - Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter core earnings down by nearly a third at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes.

AstraZeneca helped by new drugs as cholesterol pill fades

finance.yahoo.com — Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter core earnings down by nearly a third at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes. Its new lung cancer drug Tagrisso achieved stronger than expected quarterly sales

Healthy clones: Dolly the sheep's heirs reach ripe old age

sg.news.yahoo.com — By Ben Hirschler LONDON(Reuters) - The heirs of Dolly the sheep are enjoying a healthy old age, proving cloned animals can live normal lives and offering reassurance to scientists hoping to use cloned cells in medicine. Dolly, cloning's poster child, was born in Scotland in 1996. Now researchers
More Articles →
Jul 28, 2016

#AstraZeneca a bid target again, this time for #Novartis?? AZ CEO says someone may spot value ... as shares hit £50  http://reut.rs/2asVLsW 

Jul 28, 2016

#AstraZeneca earnings hit by waning #Crestor sales as core EPS falls 31% ... will new cancer drugs ride to rescue? https://t.co/hIHMtZV5RN

Jul 27, 2016

#GSK outlook brightens as #Brexit brings currency windfall - shares up 2.4% after Q2 results  http://reut.rs/2a9cIaM  via @Reuters

Jul 26, 2016

Healthy #clones: #Dolly the sheep's heirs, reassuringly, are all aging normally  http://reut.rs/2a8NrS6 


Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.